10.5 Allergen Immunotherapy, Intranasal Therapy & Treating Comorbidities
Key Takeaways
- Allergen immunotherapy is the only treatment that modifies the underlying allergic disease rather than suppressing symptoms, but severe or uncontrolled asthma is a contraindication because it carries the highest risk of fatal anaphylaxis.
- Subcutaneous immunotherapy requires a supervised observation period after every injection and immediate access to epinephrine; asthma control should be confirmed before each dose is given.
- Intranasal corticosteroids are first-line for moderate-to-severe allergic rhinitis and modestly improve asthma symptoms through the united-airway relationship, but they do not replace inhaled corticosteroids.
- Treating comorbid conditions — allergic rhinitis, chronic rhinosinusitis with nasal polyps, gastroesophageal reflux with true reflux symptoms, obesity, and obstructive sleep apnea — is a recognized management strategy when asthma remains uncontrolled on appropriate therapy.
- Empiric proton pump inhibitor therapy for asymptomatic reflux does not improve asthma control and is explicitly not recommended, a frequently tested distinction.
10.5 Allergen Immunotherapy, Intranasal Therapy & Treating Comorbidities
Quick Answer: Allergen immunotherapy is the only disease-modifying allergic therapy, but severe or uncontrolled asthma is a contraindication — uncontrolled asthma is the dominant risk factor for immunotherapy-related fatality. Intranasal corticosteroids are first-line for allergic rhinitis and modestly help asthma through the united airway, but they never substitute for inhaled corticosteroids. Among comorbidity treatments, the highest-yield exam distinction is that empiric proton pump inhibitors for asymptomatic reflux do not improve asthma control and are not recommended.
Pharmacotherapy aimed directly at the airway is only part of asthma management. Two adjacent strategies appear explicitly in the blueprint: controlling the underlying atopic disease, and treating the comorbid conditions that keep asthma uncontrolled despite adequate inhaled therapy.
Allergen Immunotherapy
Immunotherapy administers gradually increasing doses of a confirmed allergen to induce immunologic tolerance — a shift from allergen-specific IgE toward IgG4 blocking antibodies and regulatory T cell activity. Unlike every other asthma therapy, its benefit persists for years after the course ends.
Two Delivery Routes
| Feature | Subcutaneous (SCIT) | Sublingual (SLIT) tablets |
|---|---|---|
| Administration | Injections in a medical office | Dissolving tablet, first dose observed in office, then at home |
| Allergen coverage | Can combine multiple allergens | One allergen family per tablet |
| Build-up phase | Weekly to twice-weekly for several months, then monthly maintenance | Daily dosing |
| Duration of course | Typically 3 to 5 years | Typically 3 years |
| Systemic reaction risk | Higher; requires supervised observation after each injection | Lower; local oral itching and swelling are the common effects |
| Anaphylaxis preparedness | Epinephrine and resuscitation capability required on site | Epinephrine auto-injector prescribed for home use |
Candidacy and the Asthma Safety Gate
Immunotherapy is considered when symptoms correlate with a documented sensitization (positive skin prick or specific IgE that matches the clinical history) and avoidance plus pharmacotherapy have not delivered adequate control.
| Status | Immunotherapy decision |
|---|---|
| Severe or uncontrolled asthma | Contraindicated. Uncontrolled asthma is the single greatest risk factor for fatal immunotherapy reactions |
| Markedly reduced lung function | Not a candidate until lung function is stabilized; many protocols require FEV1 above roughly 70 percent predicted before dosing |
| Taking a non-selective beta-blocker | Relative contraindication — beta-blockade blunts the response to epinephrine if anaphylaxis occurs |
| Well-controlled allergic asthma with confirmed sensitization | Reasonable candidate after specialist evaluation |
| Pregnancy | Maintenance may usually continue if already tolerated; initiation or dose escalation is generally deferred |
Exam Trap: The intuitive answer — "her asthma is severe, so give immunotherapy to fix the allergy" — is exactly backwards. Severity of asthma is the reason not to start. Control the asthma first; immunotherapy is a stable-state intervention.
The Educator's Safety Role on Injection Days
- Ask about asthma symptoms and peak flow before every injection. A patient wheezing or below their green zone should not be injected that day.
- Reinforce the mandatory in-office observation period after each injection — most reactions begin within that window.
- Teach recognition of systemic reaction: generalized flushing or hives, throat tightness, wheeze, dizziness, or vomiting, all requiring immediate epinephrine, not antihistamine alone.
- Confirm the patient is not newly taking a beta-blocker, including eye drops.
Intranasal Therapy and the United Airway
The upper and lower airway share one continuous mucosa and one inflammatory process. Uncontrolled allergic rhinitis contributes to asthma symptoms through postnasal inflammatory drainage, loss of nasal air conditioning that forces cold dry mouth-breathing, and shared systemic Type 2 inflammation.
| Intranasal agent | Role | Educator counseling point |
|---|---|---|
| Intranasal corticosteroid | First-line for moderate-to-severe or persistent allergic rhinitis | Requires days to weeks of daily use for full effect — the single most common reason patients abandon it. Aim the spray away from the nasal septum toward the outer wall to prevent epistaxis and septal irritation |
| Intranasal antihistamine | Faster onset than steroid; useful alone or combined | Can cause a bitter taste and mild sedation |
| Intranasal saline irrigation | Mechanical removal of allergens and mucus; adjunct | Use distilled, sterile, or previously boiled water — never untreated tap water |
| Oral antihistamine | Controls sneeze, itch, and rhinorrhea | Second-generation agents preferred; first-generation agents cause sedation and impair performance |
| Leukotriene receptor antagonist | Treats rhinitis and asthma together | Carries the boxed warning for serious neuropsychiatric events |
Key limitation: Intranasal corticosteroids improve asthma symptoms modestly in patients with concomitant rhinitis. They are not a substitute for inhaled corticosteroids, and no amount of nasal therapy treats lower-airway inflammation.
Treating Comorbid Conditions
When asthma remains uncontrolled despite appropriate controller therapy, correct technique, and reasonable adherence, the differential shifts to comorbidity. The evidence is not uniform across conditions.
| Comorbidity | Treatment | Effect on asthma control |
|---|---|---|
| Allergic rhinitis | Intranasal corticosteroid, antihistamine, immunotherapy | Modest but real improvement in asthma symptoms |
| Chronic rhinosinusitis with nasal polyps | Intranasal steroid, saline irrigation, surgery, or dupilumab | Can substantially improve severe Type 2 asthma; polyps plus aspirin sensitivity defines aspirin-exacerbated respiratory disease |
| Gastroesophageal reflux with true reflux symptoms | Proton pump inhibitor, weight loss, meal timing, head-of-bed elevation | Improves reflux symptoms; asthma benefit is inconsistent |
| Gastroesophageal reflux, asymptomatic | Empiric proton pump inhibitor | Does not improve asthma control — not recommended |
| Obesity | Weight reduction | Weight loss improves asthma control, symptoms, and quality of life, and reduces medication requirement |
| Obstructive sleep apnea | CPAP | Improves nocturnal symptoms and asthma-related quality of life |
| Anxiety and depression | Behavioral therapy, treatment of the mood disorder | Improves adherence and symptom reporting accuracy |
| Vocal cord dysfunction / inducible laryngeal obstruction | Speech-language therapy and breathing retraining | Resolves the symptoms that were being mistaken for refractory asthma |
| Active smoking | Cessation pharmacotherapy and counseling | Restores corticosteroid responsiveness and slows lung function decline |
Exam Trap: The asymptomatic-reflux question is one of the most reliably tested items in this area. Guideline panels reviewed the trials and concluded that treating silent reflux with acid suppression in the hope of improving asthma does not work. Reserve proton pump inhibitors for patients who actually have reflux symptoms to treat.
Sequencing the Work
Asthma uncontrolled on appropriate controller therapy
│
┌───────────────┴────────────────┐
▼ ▼
Confirm the basics first: Then address comorbidity:
• Inhaler technique • Allergic rhinitis
• Adherence (AMR, counters) • Nasal polyps / rhinosinusitis
• Ongoing trigger exposure • Symptomatic reflux, obesity, OSA
• Correct diagnosis • Anxiety, depression, VCD/ILO
│
▼
Still uncontrolled with confirmed sensitization and stable lung function
│
▼
Specialist referral: immunotherapy or biologic evaluation
Escalating to immunotherapy or a biologic before verifying technique, adherence, exposure, and diagnosis is the classic sequencing error — and the classic wrong answer.
A patient with dust-mite sensitization and poorly controlled severe asthma (FEV1 55 percent predicted, two oral corticosteroid bursts this year) asks about starting allergen immunotherapy. What is the correct response?
An adult with moderate persistent asthma has no heartburn, regurgitation, or other reflux symptoms but remains symptomatic on medium-dose ICS-LABA. A colleague suggests an empiric proton pump inhibitor trial. What does the evidence support?
Which counseling point most often determines whether an intranasal corticosteroid succeeds for a patient with allergic rhinitis and asthma?